Rituximab for idiopathic membranous nephropathy

Giuseppe Remuzzi; Carlos Chiurchiu; Mauro Abbate; Verusca Brusegan; Mario Bontempelli; Piero Ruggenenti

doi:10.1016/S0140-6736(02)11042-7

Rituximab for idiopathic membranous nephropathy

Giuseppe Remuzzi, Carlos Chiurchiu, Mauro Abbate, Verusca Brusegan, Mario Bontempelli, Piero Ruggenenti

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article › peer-review

Abstract

Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m²) - the monoclonal antibody to B-cell antigen CD20 - in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p

Original language	English
Pages (from-to)	923-924
Number of pages	2
Journal	Lancet
Volume	360
Issue number	9337
DOIs	https://doi.org/10.1016/S0140-6736(02)11042-7
Publication status	Published - Sep 21 2002

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(02)11042-7

Fingerprint Dive into the research topics of 'Rituximab for idiopathic membranous nephropathy'. Together they form a unique fingerprint.

Cite this

@article{a08b12300aea4638b0ddc294aee70abf,

title = "Rituximab for idiopathic membranous nephropathy",

abstract = "Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m2) - the monoclonal antibody to B-cell antigen CD20 - in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p",

author = "Giuseppe Remuzzi and Carlos Chiurchiu and Mauro Abbate and Verusca Brusegan and Mario Bontempelli and Piero Ruggenenti",

year = "2002",

month = sep,

day = "21",

doi = "10.1016/S0140-6736(02)11042-7",

language = "English",

volume = "360",

pages = "923--924",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Lancet Publishing Group",

number = "9337",

}

TY - JOUR

T1 - Rituximab for idiopathic membranous nephropathy

AU - Remuzzi, Giuseppe

AU - Chiurchiu, Carlos

AU - Abbate, Mauro

AU - Brusegan, Verusca

AU - Bontempelli, Mario

AU - Ruggenenti, Piero

PY - 2002/9/21

Y1 - 2002/9/21

N2 - Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m2) - the monoclonal antibody to B-cell antigen CD20 - in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p

AB - Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m2) - the monoclonal antibody to B-cell antigen CD20 - in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p

UR - http://www.scopus.com/inward/record.url?scp=0037152082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037152082&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)11042-7

DO - 10.1016/S0140-6736(02)11042-7

M3 - Article

C2 - 12354476

AN - SCOPUS:0037152082

VL - 360

SP - 923

EP - 924

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9337

ER -